Efficacy of protease inhibitor monotherapyvs. triple therapy: meta‐analysis of data from 2303 patients in 13 randomized trials

Authors:

Abstract
Objectives: The aim of this analysis was to review the evidence and update a meta‐analysis evaluating the efficacy and safety results from randomized controlled trials of ritonavir‐boosted protease inhibitor (PI/r) monotherapy.Methods: A PubMed/EMBASEsearch was conducted to find randomized trials ofPI/r monotherapyvs. triple therapy in patients withHIV‐1RNAsuppression at baseline (n = 784:MONET,MONOI, Monarch andPROTEA), lopinavir/r monotherapy (n = 829:OKpilot,OK‐04, KalMo,KALESOLO,KRETA,MOSTandDREAM), atazanavir/r monotherapy (n = 103:MODAT), or all three (n = 587:PIVOT).HIV‐1RNAplasma suppression was lower in thePI/r monotherapy arm compared with the triple therapy arm in the switch‐equals‐failure analysis [difference −8.3%; 95% confidence interval (CI) −11.9 to −4.8%], but not when intensification was included (difference 0.5%; 95%CI−2.5 to 3.6%). Rates of resistance mutations were similar between arms, as was overall neurocognitive function.Conclusions: PI/r monotherapy showed a higher risk of plasmaHIV‐1RNAelevations. However, there was no increased risk of treatment‐emergent drug resistance, neurocognitive endpoints did not differ, andHIV‐1RNAsuppression rates after intensification were similar betweenPI/r monotherapy and triple therapy.

This publication has 30 references indexed in Scilit: